Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068309 | 0.84 | NAMPT (0.50) | KMT2AMEN1ALDH1A1HPGDLMNA | |
| SCHEMBL7069769 | 0.82 | POLB (0.50) | SMN1; SMN2HTTALDH1A1KDM4EHDAC6 | |
| SCHEMBL7070258 | 0.81 | PLAU (0.53) | KMT2AMEN1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL7400914 | 0.81 | HDAC6 (0.49) | SMN1; SMN2HTTALDH1A1HPGDHSP90AA1 | |
| SCHEMBL7123647 | 0.81 | ALDH1A1 (0.49) | SMN1; SMN2HTTALDH1A1LMNAMAPT | |
| SCHEMBL7069837 | 0.79 | ALDH1A1 (0.47) | KMT2AMEN1HTTALDH1A1HPGD | |
| SCHEMBL7071936 | 0.78 | TLR9 (0.48) | ALDH1A1HDAC6 | |
| SCHEMBL7073473 | 0.77 | HTR2C (0.47) | KMT2AMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL7070115 | 0.77 | NPSR1 (0.49) | SMN1; SMN2ALDH1A1HPGDHSP90AA1LMNA | |
| Trifluoroacetic Acid SCHEMBL7067787 | 0.77 | MLYCD (0.49) | SMN1; SMN2HTTALDH1A1HPGDHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | KMT2A 3958/4885MEN1 2587/4885SMN1; SMN2 1710/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | KMT2A 3040/4885MEN1 3772/4885SMN1; SMN2 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.